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Background: Patients are at risk of drug-related problems (DRPs) at transition points during hospitalization. The
community pharmacist (CP) is often the first healthcare professional patients visit after discharge. CPs lack sufficient
information about the patient and so they may be unable to identify problems in medications, which may lead to
dispensing the wrong drugs or dosage, and/or giving wrong information. We aim to assess the impact of a
complex intervention comprising of medication reconciliation performed at discharge by a hospital pharmacist
(HP) with communication between the HP and CP on DRPs during the seven days following discharge.
Methods/Design: The study is a cluster randomized crossover trial involving 46 care units (each unit corresponding
to a cluster) in 22 French hospitals during two consecutive 14-day periods, randomly assigned as ‘experimental’ or
‘control’ (usual care) periods. We will recruit patients older than 18 years of age and visiting the same CP for at least
three months. We will exclude patients with a hospital length of stay of more than 21 days, who do not return
home or those in palliative care. During the experimental period, the HP will perform a medications reconciliation
that will be communicated to the patient. The HP will inform the patient’s CP about the patient’s drug therapy
(modification in home medication, acute drugs prescribed, nonprescription treatments, and/or lab results). The
primary outcome will be a composite outcome of any kind of drug misuse during the seven days following
discharge assessed at day seven (±2) post-discharge by a pharmacist in charge of the study who will contact both
patients and CPs by phone. The secondary outcome will be unplanned hospitalizations assessed by phone contact
at day 35 (±5) after discharge. We plan to recruit 1,176 patients.
Discussion: This study will assess the impact of a reconciliation of medications performed at patient discharge
followed by communication between the HP and the patient’s CP. It will allow for identifying the type of patients
in France for which the intervention is most relevant.
Trial registration: This study was registered with ClinicalTrials.gov (number: NCT02006797) on 5 December 2013.
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Drug-related problems (DRPs) are defined as an ‘event
or circumstance involving drug therapy that actually or
potentially interferes with desired health outcomes’ [1].
These problems are the cause of about 11% of the iatro-
genic problems and could be avoided.
In France, the national survey of all serious adverse
events associated with care (ENEIS) showed that 1.3% of
hospitalizations (between 100,000 and 120,000 a year)
are due to a serious drug-related iatrogenic event and
are therefore avoidable [2]. Furthermore, more than half
occur after a new prescription at admission or during
discharge. In fact, the French health authority, through
an accreditation procedure, requires hospitals to ensure
treatment continuity from admission to discharge [3].
An estimated 7 to 30% of patients present a DRP at hos-
pital admission [4]. A reconciliation of medications sup-
ported by efficient communication between the hospital
staff and community pharmacists (CPs), in addition to a
standard patient interview and a general practitioner’s
examination of prescriptions, was found to be effective in
identifying medication discrepancies for inpatients [5,6].
Approximately 25 to 87% of patients experience DRPs
after hospital discharge [7-14]. Drug reconciliation be-
fore discharge was also found to be effective and could
decrease DRPs by 50% when performed by a medical
and/or pharmaceutical team; pharmaceutical teams were
more effective in this process than medical or nursing
teams [15-18].
Medication reconciliation is defined as the formal
process of checking the complete, accurate list of a pa-
tient’s previous medication and comparing it with the
prescriptions after a transition of care (on admission,
after transfer to another medical unit, and at discharge)
[19]. The process has been recommended since 2005 by
the Joint Commission on Accreditation to prevent er-
rors. Countries such as Germany, the Netherlands, and
France are involved in the World Health Organization
(WHO) High 5’s procedure and particularly in medica-
tion reconciliation at admission [20,21]. Discrepancies
between hospital treatment and home medication must
be discussed with the prescriber and modifications made
if necessary [19]. In fact, non-intentional discrepancies
(NIDs) or intentional discrepancies (IDs) may be ob-
served. An ID is a voluntary change in the patient’s
medication (unnecessary drugs, route or dose change, or
conformation to the hospital formulary). NIDs (wrong
route or dose, missing treatment, or added drug) are
considered medication errors. Among NIDs, 40 to 59%
are potential causes of adverse events and 33% actually
lead to adverse events [19].
Several experiments have been conducted in North
America or Europe to increase the quality of information
at discharge, considering that well-informed patientsand/or caregivers can manage the drug treatment on
their own. However, few studies have focused on the role
of the CP at discharge, both in the reconciliation process
and/or the information needed to reduce DRPs (such as
the medical discharge letter) [22,23].
The primary objective of this study is to investigate a
hospital pharmacist (HP) performing a reconciliation of
medications with the patient at discharge, followed by
communication between the HP and the CP, and their im-
pact on the incidence of DRPs in patients during the seven
days after discharge. The potential harmfulness of DRPs
will be appraised by an expert committee. Secondary ob-
jectives are patient satisfaction and subgroup analyses.
Methods/Design
Design
This study will be a cluster randomized crossover con-
trolled trial. The clusters will be hospital units, each in-
volved during two consecutive 14-day periods (one when
the assessed intervention will apply and the other as the
control period). For each unit, the order of the two pe-
riods will be randomized (intervention followed by con-
trol, or vice versa).
We planned the study as a cluster trial because of meth-
odological issues. Indeed, randomization of patients would
have implied fully informing them of the study, thus in-
creasing the risk of group contamination. Conversely, ran-
domizing clusters allows for patients to receive partial
information; patients included in the usual care group will
be unaware that some patients will have a reconciliation
procedure performed at discharge. Therefore, we planned
the study as a crossover trial because: 1) the risk of cross-
contamination is minimal (residual effect on a short
period is null); 2) even if a residual effect exists, it is a su-
periority test that would lead to minimizing the interven-
tion effect; 3) the crossover trial allows for increasing the
statistical power and thereby balancing the power lost
with the cluster design [24]; and 4) a crossover design of-
fers better balance between groups, which is of import-
ance in our study due to the high heterogeneity in units.
Setting and participants
In total, 22 French HPs working in hospitals all over the
French country have agreed to participate. Each HP se-
lected two units (one surgical, one medical) in their hos-
pital. Units for which a pharmaceutical reconciliation
procedure at admission or discharge was already in place
were not eligible. The medical heads of the units also
agreed to participate. We will exclude patients with a
length of stay of more than 21 days (as there can be too
many therapeutic modifications during the stay), who do
not return home, who are in palliative care and/or near
the end of life, and who are not able to understand the
topic.
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ticipate by the inclusion of their patients in the study.
They will be informed of the study in three ways: a pro-
fessional journal supported by the pharmacist unions, a
professional journal supported by the national council of
the order of pharmacists, and a letter sent by the study
scientific committee distributed by wholesale drug
distributors.
Outcomes
The primary outcome is a composite one comprising of
any problem or dysfunction observed during the seven
days after discharge. More specifically, we will consider
any of the following problems: 1) the drug is not the cor-
rect one (name, form, route, or dose); 2) the patient does
not take what was prescribed and/or takes treatments
that should have been stopped; and 3) the patient could
not obtain the medication when visiting the pharmacy,
which causes a gap in the continuity and duration of
therapy.
The primary outcome will be assessed at day seven
(±2) after discharge, by a pharmacist specifically recruited
for the study. This pharmacist will contact both patients
and CPs by phone to assess the possible incidence of a
DRP after discharge.
For each DRP, an expert committee composed of
physicians (one nephrologist, one cardiologist, oneIdentify the regular CP of patient
Medication reconciliation at admission/discharge in line with
Problem No problem 
Writing the summary document to the CP
Patient information 
(Therapeutic modification: dose modified, stop drugs, drug replacem
synthesis of patient’s talk communicated to CP
Figure 1 REPHVIM study - flow of the intervention. CP, community phagastroenterologist, and a clinical pharmacist) will assess
the potential medical impact of the DRP in terms of its se-
verity (from 0: no problem, to 3: life-threatening) using
Bayliff ’s scale [25]. The severity of the identified DRP will
be one of the secondary outcomes.
Other secondary outcomes will be: 1) the number of
non-planned hospitalizations during the 35 days after
discharge (assessed by phone by the pharmacist re-
cruited for the study); and 2) patients and CP satisfac-
tion (assessed at day seven with a four-item Likert scale
by phone). We will also assess the time taken by the HP
to perform the intervention (medication reconciliation
and communication to CP) and the proportion of drug
prescriptions modified by the HP at discharge. DRP will
be studied in following five subgroups: 1/less or over or
equal to 75-years-old, 2/less or over or equal to 4 drugs
prescribed 3/expensive or not-expensive medication 4/
surgery or medical-unit and 5/planned or non-planned
hospitalization.
Intervention
The flow of the intervention is outlined in Figure 1. In
the experimental group, the HP will be in charge of the
discharge reconciliation and its communication to the
CP. To standardize this nonpharmacological intervention
over the different hospitals [26], HPs will receive training
in the reconciliation procedure by an experienced clinical the regular CP
ent…)
Intervention
Documents sent by securized software
Prescription modification
rmacists.
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Clinical Pharmacy (SFPC).
The intervention consists of: 1) identifying the patient’s
regular CP, 2) completing a short document including the
reason for hospitalization, therapeutic modifications in
terms of the home medication, and lab results necessary
to understand and/or accept the prescription (estimated
glomerular filtration rate, Na and K levels, coagulation re-
sults, and so on), 3) controlling the discharge prescription
and, if needed, discussing it with the physician and record-
ing it on the SFPC card [27], 4) explaining the treatment
to the patient and the modifications made, 5) phoning the
CP to explain the patient’s inclusion in the study, the
discharge time, and the modifications in treatment, and
6) sending the CP the prescription sheet via a secure
email before patient discharge. The CP will then receive
visits from the patient or caregiver as usual. For the
control group, pharmaceutical care will be performed as




D0  D0 D +3/+
CP identification












Figure 2 REPHVIM Study - synopsis of the study.no contact with the CP. REPHVIM study is outlined in
Figure 2.
Blinding
Because of the nature of the assessed intervention, blind-
ing will not be possible for patients or care providers
(HPs and CPs). Also, we did not include a blinded out-
come assessor because blinding could be easily broken
when contacting patients and CPs. Therefore, the present
study is fully open, without reliable blinding. The only
blinded outcome is a secondary one; the expert committee
in charge of assessing the potential medical impact of the
DRP will be blinded.
Sample size calculation
This study is a superiority trial with a binary decision
criterion. We hypothesized a DRP rate of 45% in the ex-
perimental group as compared to 60% in the control
group [7]. Considering a 90% power and a 5% two-sidedPharmacists in charge of the study (PCS)




questionnaire [patient and CP]
-Data entry in eCRF by PCS
-Telephone 
questionnaire [patient]
-Data entry in eCRF by PCS
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a trial of two parallel, individually randomized groups.
We used a sample size calculation software (nQuery Ad-
visor -2005- Version 6.0 Los Angeles, CA. Copyright ©
2005 by Janet D. Elashoff). In addition, because the trial is
a cluster randomized crossover trial, we assessed both
intraclass and interclass correlations [24,28]. We there-
fore applied an inflation factor equal to:
1 þ P –1ð Þρ−Pη ð1Þ
where P is the number of patients in a cluster, ρ is the
intraclass correlation coefficient and η is the interclass
correlation coefficient. We considered a high value for
the intraclass correlation coefficient because the out-
come is a process, and because of the incidence of about
50% [29]. Naturally, η is expected to be lower than ρ,
and we chose the value of η to be half that of ρ as ad-
vised [24]. We will use a value of 0.2 for ρ and 0.1 for η.
Because we identified 46 units, we planned to recruit
10.2 patients in each unit for each period. We plan to
perform a sensitivity analysis excluding patients without
data at day seven after discharge, and so we fixed the
number of patients to be recruited in each period to 14.Table 1 Centers and names of the units which agreed to part
Hospital Unit 1 Un
CH ALES Medical Ab
CHU ANGERS Infectious diseases Ab
CH BETHUNE Nephrology & rheumatology Ab
CH BLOIS Cardiology
CHU BREST Gastro-enterology Uro
CHU CLERMONT-FERRAND Medical Ab
CH COLMAR Medical Ort
CH COMPIEGNE Cardiology Ort
CHU GRENOBLE Geriatric
CH LE HAVRE Rheumatology Ab
AP-HM (MARSEILLE) Medical Ab
CH METZ Medical Ab
CH LE MANS Rheumatology Ab
CH NEVERS Medical Ab
CHU NICE Gastro-enterology Ab
CHU NIMES Cardiology Uro
CHU POITIERS Cardiology Ort
CHRU STRASBOURG Oncology Ab
CHU TOULOUSE Rheumatology Vas
HIA BEGIN Infectious diseases Ab
CHU TOURS Cardiology Vas
CHU REIMS Unit 1 UnIn the end, we expect to recruit 14 patients in each of
the 46 units in each period, for 1,176 patients.
Statistical analysis
The primary analysis will be conducted within the
framework of a hierarchical model, inspired by the work
of Turner et al. [30]. Under this model, two levels of
correlation are considered: intra-cluster correlation and
cross-correlation period. Secondary outcomes will also
be analyzed with hierarchical models. Subgroup analyzes
will consider patient characteristics (age and pathology),
drugs classes, nature of the unit (surgery or medical),
number of home treatments, day of discharge (weekday
or weekend), whether it is an expensive drug (more than
150€ per unit) is prescribed, and whether some medica-
tions require temperature control.
Funding source and regulatory aspects
This study is sponsored by the French Ministry of Health
(PREPS 2012 number 12-10-0054). The CHRU of Tours is
the promoter and is in charge of all the administrative
measures. The local ethics committee (CPP TOURS -
Region Centre - Ouest 1) approved the study for all cen-
ters. Indeed, French legislation requires just one ethic
committee’s approval for all centers. We were asked byicipate to the study
it 2 Unit 3 Unit 4
dominal surgery
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signed commitment from all the heads of the involved
care units. In Table 1 we report the list of those units.
Also as authorized by French law, the requirement for
patient written consent was not necessary and only in-
formation about the study was to be given to patient
[31]. In fact the patient can always refuse to participate.
The French committees for data handling (CCTIRS and
CNIL) approved the study. This trial was registered with
ClinicalTrials.gov (number NCT02006797 on 5 December
2013, Relation between hospital and community pharma-
cists and drug-related problems (REPHVIM)).Dissemination
The scientific committee will be in charge of the publi-
cations to report the results of the present study. Re-
ports will follow the CONSORT statement and its
extensions (for both cluster randomized trials and non-
pharmacological interventions), as well as the TIDER
checklist.Discussion
This study will investigate the effect of HP reconciling
medications with the patient at discharge and communi-
cating with the patient’s CP on preventing DRPs. The sub-
groups study will evaluate the patients for which the
process would be efficient. The French Society of Clinical
Pharmacy is expected to write recommendations and pro-
mote communication between HPs and CPs. We expect a
decrease in DRPs from 60 to 45%.
The success of the study depends on the ability of the
HP to enroll patients in the study. The units have been
chosen for their possibility of having more than one dis-
charge a day. Most are surgery units (orthopedic, urology,
or general surgery) and medical units (nephrology, gastro-
enterology, internal medicine, and so on) with a large
number of beds (more than 20) and a mean length of stay
from 5 to 11 days. Patients in the intervention group need
to spend only a few minutes of discussion with the HP.
This intervention will need to be performed as soon as
possible once discharge is planned. Indeed, at discharge,
patients are usually stressed with transport and other ad-
ministrative issues, so they may be less receptive to discuss
their treatment.
To optimize and standardize the intervention assessed,
the scientific committee has established a training pro-
gram for HPs. Also, quality documents have been written
to ensure performance of the same intervention. Outcome
assessments will be performed centrally by two pharma-
cists (pharmacists in charge of the study) specially re-
cruited for the study, which will favor homogeneity in the
phone interviews.Trial status
At this time, 44 units have been recruited since 21 January
2014 and 340 patients have been included.
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